Noticias de PFE
Noticias del mercado
Últimas noticias sobre PFE — 281 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Pfizer (PFE) alcanzó los 26,48 dólares al cierre del último día de negociación, lo que refleja un cambio del -1,16% en comparación con su último cierre.
Pfizer Inc. stock underperforms Tuesday when compared to competitors
Hikma, Cipla Cut Deals In Pfizer Heart Drug Patent Case
Pfizer secures deals to keep heart drug free of generic rivals until 2031
Pfizer reaches settlement agreements with Dexcel Pharma, Hikma & Cipla for Vyndamax
Pfizer Stock Is Declining Today: What's Happening?
Should You Buy, Sell, or Hold Pfizer at $27?
Pfizer secures deals to keep heart drug free of generic rivals until 2031
Morgan Stanley reiterates Equalweight on Pfizer stock at $28
Pfizer’s Deal With Hikma Ends Patent Trial on Vyndamax Copy (1)
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) (BBIO:NASDAQ)
Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
Are Wall Street Analysts Bullish on Pfizer Stock?
Pfizer identifies new GIPR antagonists
Pfizer Inc. (PFE) Files Form 8-K with SEC
Pfizer Shareholders Reaffirm Leadership, Governance at 2026 Meeting
El director de Pfizer, Mortimer J. Buckley, recibió 7.686,539 unidades de acciones fantasma como compensación diferida, lo que elevó su tenencia total de acciones fantasma a 24.391,124 unidades vinculadas a acciones de Pfizer.
Página 8 de 15
